In comparison with FGF21 therapy, CH-FGF21 administration inhibited the levels of AST and ALT released from hepatocytes into blood significantly during ALI progression (Supplementary Figure S4). This evidence concerns the gene FGF21 and acute respiratory distress syndrome.